Biosortia Pharmaceuticals Creating Drug Discovery Opportunity with Previously Unstudied Microorganisms. Dublin, Ohio (February 26, 2013) – The Ohio State University has signed an agreement with Biosortia Pharmaceuticals of Dublin, Ohio to discover new biologically active natural products with potential anti-cancer activity. Potential candidate compounds discovered during the Biosortia-sponsored research project will primarily be tested against human

Biosortia Pharmaceuticals Hires Kurt Dieck as President and CEO to Accelerate Strategy to Develop and License New Highly Active Compounds from Unculturable Aquatic Microbial Consortia Dublin, Ohio (January 22, 2013) – Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead the early-stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named

Algae Sampling Technology Partnership to Find, Exploit Novel Chemical Compounds Published (October 30, 2012) – A pharmaceutical research and development startup and NOAA signed an agreement designed with two goals in mind. The company, Biosortia, plans to discover and extract beneficial compounds from natural sources such as algae, and the National Centers for Coastal Ocean Science